D. E. Shaw & Co., Inc. Halozyme Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 306,612 shares of HALO stock, worth $14.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

306,612

Holding current value

$14.6 Million

% of portfolio

0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$51.3 - $64.42 $8.83 Million - $11.1 Million	-172,163 Reduced 35.96%	306,612 $17.5 Million
Q2 2024 Aug 14, 2024	BUY	$37.81 - $52.4 $6.83 Million - $9.47 Million	180,650 Added 60.6%	478,775 $25.1 Million
Q1 2024 May 15, 2024	BUY	$33.68 - $41.95 $9.18 Million - $11.4 Million	272,549 Added 1065.64%	298,125 $12.1 Million
Q4 2023 Feb 14, 2024	BUY	$33.32 - $42.1 $117,519 - $148,486	3,527 Added 16.0%	25,576 $945,000
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $395,554 - $477,681	10,849 Added 96.87%	22,049 $842,000
Q2 2023 Aug 14, 2023	SELL	$30.28 - $38.74 $474,972 - $607,675	-15,686 Reduced 58.34%	11,200 $403,000
Q1 2023 May 15, 2023	SELL	$32.86 - $55.7 $114,977 - $194,894	-3,499 Reduced 11.52%	26,886 $1.03 Million
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $134,922 - $200,193	3,368 Added 12.47%	30,385 $1.73 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $112,392 - $151,042	2,917 Added 12.1%	27,017 $1.07 Million
Q2 2022 Aug 15, 2022	SELL	$37.35 - $48.3 $394,901 - $510,675	-10,573 Reduced 30.49%	24,100 $1.06 Million
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $6.18 Million - $7.94 Million	-193,434 Reduced 84.8%	34,673 $1.38 Million
Q4 2021 Feb 14, 2022	BUY	$31.82 - $40.75 $57,148 - $73,187	1,796 Added 0.79%	228,107 $9.17 Million
Q3 2021 Nov 15, 2021	SELL	$38.47 - $46.42 $8.12 Million - $9.8 Million	-211,087 Reduced 48.26%	226,311 $9.21 Million
Q2 2021 Aug 16, 2021	SELL	$38.84 - $51.31 $16.7 Million - $22.1 Million	-431,065 Reduced 49.64%	437,398 $19.9 Million
Q1 2021 May 17, 2021	SELL	$39.51 - $51.45 $16.8 Million - $21.9 Million	-425,741 Reduced 32.9%	868,463 $36.2 Million
Q4 2020 Feb 16, 2021	SELL	$25.81 - $43.62 $27.8 Million - $47.1 Million	-1,078,709 Reduced 45.46%	1,294,204 $55.3 Million
Q3 2020 Nov 16, 2020	BUY	$25.74 - $29.63 $7 Million - $8.06 Million	272,027 Added 12.95%	2,372,913 $62.4 Million
Q2 2020 Aug 14, 2020	BUY	$16.25 - $26.81 $3.21 Million - $5.29 Million	197,293 Added 10.36%	2,100,886 $56.3 Million
Q1 2020 May 15, 2020	SELL	$13.9 - $21.83 $2.39 Million - $3.75 Million	-171,630 Reduced 8.27%	1,903,593 $34.2 Million
Q4 2019 Feb 14, 2020	BUY	$14.93 - $19.53 $22.8 Million - $29.8 Million	1,526,558 Added 278.23%	2,075,223 $36.8 Million
Q3 2019 Nov 14, 2019	SELL	$15.2 - $17.69 $71,759 - $83,514	-4,721 Reduced 0.85%	548,665 $8.51 Million
Q2 2019 Aug 14, 2019	BUY	$14.75 - $17.26 $3.44 Million - $4.03 Million	233,400 Added 72.94%	553,386 $9.51 Million
Q1 2019 May 15, 2019	SELL	$13.94 - $17.58 $1.16 Million - $1.46 Million	-82,898 Reduced 20.58%	319,986 $5.15 Million
Q4 2018 Feb 14, 2019	BUY	$13.33 - $18.66 $436,170 - $610,573	32,721 Added 8.84%	402,884 $5.89 Million
Q3 2018 Nov 14, 2018	BUY	$16.68 - $18.41 $2.83 Million - $3.12 Million	169,425 Added 84.4%	370,163 $6.73 Million
Q2 2018 Aug 14, 2018	BUY	$16.87 - $20.3 $2.18 Million - $2.62 Million	129,054 Added 180.03%	200,738 $3.39 Million
Q1 2018 May 15, 2018	SELL	$17.06 - $21.2 $3.09 Million - $3.84 Million	-181,052 Reduced 71.64%	71,684 $1.4 Million
Q4 2017 Feb 14, 2018	SELL	$16.75 - $20.8 $2.09 Million - $2.59 Million	-124,620 Reduced 33.02%	252,736 $5.12 Million
Q3 2017 Nov 14, 2017	BUY	$11.76 - $17.4 $4.44 Million - $6.57 Million	377,356	377,356 $6.56 Million

Others Institutions Holding HALO

# of Institutions

544

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.65B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account